Skip to main content
Caplight Logo









FUSE-AI

FUSE-AI

Private
HamburgHealthcare & Life Scienceshttps://fuse-ai.de

Last Round

M&A

Dec 23, 2024

Est. Valuation

$88.34M

Total Funding Raised

$1.21M

Company Overview

FUSE-AI is a German e-health company that develops artificial intelligence and deep learning-based software solutions for the clinical sector, specifically for radiology.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Subscription SaaS

AI Layer

Application

Keywords

medical imagingradiology AIprostate cancer detectionpicture archiving and communication systemPACSAI diagnostic softwarecomputer visionmedical softwarehealthcare analyticsdigital healthe-healthmedtechclinical decision supportDICOMAI second opinion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FUSE-AI Comparables

Compare FUSE-AI with similar companies based on industry and business-model similarity.

FUSE-AI comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lucida Medical
88%
Bot Image, Inc.
86%
Quibim
79%

FUSE-AI Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&ADec 23, 2024
GrantAug 3, 2023
AcceleratorNov 3, 2022
AcceleratorMar 11, 2022
SeedOct 9, 2019

Key People

Founding team and executive leadership

Andreas Raguse

CTO

Executive Team

Leonard W.

Chief Technology Officer

Executive Team

Juri Rohde

COO Incl. Management, Business Development, Strategy, Etc., Head Of Operations Incl. Product Development, Head Of Q R (QMR, PRRC)

Executive Team

FUSE-AI Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 2, 2026

    AI-based prostate cancer diagnosis software now available in the European market.

  • Aug 3, 2023

    Received grant funding from German Accelerator.

FUSE-AI Filings

Explore SEC and related filing metadata, where available.

FUSE-AI filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FUSE-AI's valuation, stock price, and market status.

Is FUSE-AI a public or private company?

FUSE-AI is a private company.

What is the current stock price of FUSE-AI?

FUSE-AI is a private company, so its shares have no public market price. Caplight tracks FUSE-AI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is FUSE-AI worth (valuation)?

FUSE-AI's valuation is estimated at $88.3M based on funding round data.

Can I buy FUSE-AI stock?

FUSE-AI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was FUSE-AI's last funding round?

FUSE-AI's most recent funding round was M&A on December 23, 2024.

Who are the main investors in FUSE-AI?

Key investors in FUSE-AI include AI.STARTUP.HUB Hamburg, Pineapple Power Corporation PLC, Xlife Sciences AG.

Will FUSE-AI IPO soon?

No public IPO plans have been announced for FUSE-AI.

How can I track FUSE-AI secondary market activity?

Caplight tracks bids, offers, and trades in FUSE-AI's shares on secondary markets.

Firmographic Details

HeadquartersHamburg
Employee Range17
Year Founded2017
Last FundingDec 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?